08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Schroedinger completes venture financing

Schroedinger Inc. , New York, N.Y.   Business: Computational chemistry/biology   Date completed: 12/19/12   Type: Venture financing   Raised: $20 million   Investor: Cascade Investment   Note: Cascade Investment is wholly owned by Bill...
07:00 , Sep 6, 2004 |  BioCentury  |  Finance

Ebb & Flow

After a busy summer, CoTherix last week got its IPO back on track. The deal was postponed in June, and in July, W. Scott Harkonen stepped down as CEO and a director. In its Thursday...
07:00 , Apr 12, 2004 |  BC Extra  |  Top Story

Corus raises $60 million

Corus Pharma (Seattle, Wash.) raised $60 million in a series C round led by Bear Stearns. Other investors included Hambrecht & Quist; AIG Sun America Ventures; MPM BioEquities; the Carnegie Group; JP Morgan; Novo A/S;...
08:00 , Mar 29, 2004 |  BioCentury  |  Strategy

All that Jazz . . .

All that Jazz . . . Company Raised Date Focus Investors Jazz $250.0 3/24/04 Neurology, cancer, endocrine Kohlberg Kravis Roberts; Prospect Venture Partners; Versant Ventures; Beecken Petty O'Keefe; Golden Gate Capital; Thoma Cressey Equity Partners;...
08:00 , Mar 10, 2003 |  BioCentury  |  Finance

Ebb & Flow

For those who think an M&A announcement represents the endgame for a biotech company, last week's maneuverings surrounding the proposed takeouts of Corvas (CVAS) and Oxford GlycoSciences (LSE:OGS; OGSI) provides notice that a deal may...
08:00 , Mar 7, 2003 |  BC Extra  |  Top Story

Corus raises $40 million

Respiratory and infectious disease company Corus Pharma (Seattle, Wash.) raised $40 million in a series B round led by Novo; RBC Capital; and JPMorgan. Other investors included MDS Capital; Integra Ventures; Burrill; OrbiMed; Cascade Investment;...
07:00 , Jun 6, 2001 |  BC Extra  |  Financial News

Corus raises $18.5 million

Corus (Seattle, Wash.) raised $18.5 million in a private financing. Investors included Burrill & Co.; Cascade Investment; JPMorgan Partners; and OrbiMed Advisors. Corus is developing therapeutics to treat respiratory disorders and infectious diseases....
08:00 , Mar 20, 2000 |  BioCentury  |  Finance

Hitting the potholes

It's too early to say the party's over, but the path to riches is beginning to show cracks in its pavement. The BioCentury 100 suffered its second consecutive big weekly loss, dropping 18 percent last...
08:00 , Mar 14, 2000 |  BC Extra  |  Financial News

Seattle Genetics raises $30 million

Bank of America Ventures led the venture financing, which will help fund the company's clinical trials of monoclonal antibodies for cancer. Other investors included Cascade Investment; Vulcan Ventures; Olympic Venture Partners; Sofinnova Ventures; and Indosuez...
08:00 , Feb 28, 2000 |  BioCentury  |  Finance

The biotech economy

As Old Economy stocks tanked on the Big Board last week, Celera (CRA) demonstrated the new muscle of the biotech space in the New Economy. Stock of the genomics play split 2-1 before the week's...